1047644-62-1Relevant articles and documents
Preparation method of Afuresertib
-
Paragraph 0036-0039, (2020/09/08)
The invention discloses a preparation method of Afuresertib. The Afuresertib is prepared through an amidation reaction and an ammoniation reduction reaction between (2S)-2-amino-3-(3-fluorophenyl) methyl propionate and 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxylic acid. The preparation method has the advantages of easily available raw materials, simple process, optimized environment and improved quality, and is suitable for industrial amplification requirements.
Preparation method of Afuresertib
-
, (2020/09/16)
The invention discloses a preparation method of Afuresertib. The preparation method comprises the following steps: firstly preparing a chiral compound (alpha S)-alpha-amino-3-fluorophenyl propionitrile, and carrying out amidation reaction and nitrile group reduction reaction on the chiral compound (alpha S)-alpha-amino-3-fluorophenyl propionitrile and 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxylic acid to obtain the target product Afuresertib. The preparation method is simple in process, mild in condition, optimized in environment, improved in quality and suitable for therequirement of industrial amplification.
AFURESERTIB: Protein kinase B (PKB) inhibitor Oncolytic
Conkel,Benson
, p. 541 - 546 (2014/12/11)
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays key roles in cellular proliferation and survival. Mutations and alterations in this signal transduction pathway have been described in a variety of solid and hematopoietic malignancies, which may contribute to perpetuation of the disease in a number of ways. Increasing interest in targeting particular facets of this signaling cascade has led to the development of a number of novel anticancer agents, including afuresertib (GSK-2110183), an orally bioavailable pan-inhibitor of the RAC-alpha serine/threonine protein kinase, also referred to as protein kinase B or proto-oncogene c-Akt. The present review summarizes the preclinical and pharmacological aspects of afuresertib and early clinical experience.